Management of severe hypertension in the postpartum period with intravenous hydralazine or labetalol: a randomized clinical trial.
OBJECTIVE
To compare the safety and efficacy of intravenous labetalol and intravenous hydralazine for acutely lowering blood pressure in the puerperium.


METHODS
Randomized clinical trial.


METHODS
Critical care unit of gynecology and obstetrics department in the Complejo hospitalario "Dr. AAM" de la Caja de Seguro Social in Panama.


METHODS
Eighty-two women with severe hypertension during the postpartum period.


METHODS
Patients were randomized to receive hydralazine (5 mg as a slow bolus dose given intravenously, and repeated every 20 minutes to a maximum of five doses) or labetalol (20 mg in an intravenous bolus dose followed by 40 mg if not effective within 20 minutes, followed by 80 mg every 20 minutes to a maximum dose of 300 mg). The primary endpoint was the successful lowering of blood pressure. Secondary endpoints were maternal complications and side-effects.


RESULTS
Forty-two women were enrolled in the hydralazine group and 40 in the labetalol group. Women were similar with respect to characteristics at randomization. No significant differences were observed for persistent severe hypertension or maternal side-effects. There was only one case of persistent severe hypertension in the labetalol group. There were no maternal deaths in any of the women studied.


CONCLUSIONS
This randomized clinical trial shows that intravenous hydralazine and intravenous labetalol are effective and safe in the management of severe hypertension in the postpartum period.
Vigil-De Gracia
Paulino
P
Obstetric Intensive Unit, Department of Gynecology and Obstetrics, Complejo Hospitalario "Arnulfo Arias Madrid" Caja de Seguro Social, Panamá, Panamá
Ruiz
Esteban
E
López
Juan C
JC
de Jaramillo
Ilka Alveo
IA
Vega-Maleck
Juan C
JC
Pinzón
Jaime
J
D000328:Adult; D000704:Analysis of Variance; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000008:administration & dosage / Q000627:therapeutic use*; D046110:Hypertension, Pregnancy-Induced / Q000188:drug therapy* / Q000503:physiopathology; D007262:Infusions, Intravenous; D007741:Labetalol / Q000008:administration & dosage / Q000627:therapeutic use*; D010176:Panama; D049590:Postpartum Period; D012107:Research Design; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000959:Antihypertensive Agents; D006830:Hydralazine; D007741:Labetalol